US EditionEli Lilly's Oral GLP-1 Pill Achieves Key Milestones in Diabetes and Weight Loss Treatment
- Eli Lilly's experimental oral drug, Orforglipron, helped patients with Type 2 diabetes lose an average of 16 pounds over 26 weeks during a clinical trial.
- The trial results indicated that Orforglipron's effectiveness compares favorably with Ozempic, which helped patients lose around 6% of their body weight.
- Eli Lilly plans to seek regulatory approval for Orforglipron for weight management by the end of 2024 and for Type 2 diabetes in early 2026, according to CEO David Ricks.
- Eli Lilly's shares surged by 15% following the trial results, indicating a strong market reaction, while shares for Novo Nordisk dropped by 3.9% amid competitive concerns over Orforglipron.
94 Articles
94 Articles
What is the weight-loss drug Orfoglipron and could it replace Ozempic?
The once dailly pill is still going through trials (Picture: Getty) Ozempic has skyrocketed in popularity within the past two years, causing Weight Watchers to file for bankruptcy. But the popular injection is seeing new competition with Mounjaro, and now a daily pill which could help patients lose 16 pounds in just nine months. The pill Orforglipron is used to treat Type 2 diabetes and obesity, and trials have shown participants had lower blood…
Watauga Democrat
knoxvilledailysun.comFirst Weight-Loss Pill From Lilly Shows Promising Results
Key Takeaways
Novo Nordisk Is Getting Absolutely Destroyed
Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over eight percent on Thursday, after its main competitor in the space, US-based pharmaceutical company Eli Lilly, announced promising Phase 3 trial results for its GLP-1 pill orforglipron, which is being marketed under its brand name CagriSema. According t…
Who could take new weight-loss pill - and who should avoid it
The first daily weight-loss pill is expected to be available in the UK as soon as next year after a trial found it to be effective in treating obesity and diabetes.The drug, developed by Eli Lilly and called orforglipron, targets the same GLP-1 receptors as Ozempic, Wegovy and Mounjaro.If the drug gets approved by regulators, it would be a more convenient option that is expected to reach blockbuster status.Here, The i Paper takes a look at what …
Eli Lilly Skyrockets After Promising Results for First Weight-Loss Pill
After the tireless, incredible work by the scientists involved, the marketing team will barely have to lift a finger to come up with something catchier than orforglipron, as the company’s potentially game-changing drug has been dubbed. Eli Lilly announced trial results Thursday that suggested the experimental pill for diabetes and weight loss is just as effective as rival Novo Nordisk’s blockbuster injectable diet drug Ozempic. The company plans…
Coverage Details
Bias Distribution
- 55% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
